On October 2, 2025, CytoMed Therapeutics Limited announced the publication of a preclinical study in collaboration with the University of Texas MD Anderson Cancer Center. The study, titled “Donor‑Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising Off‑the‑Shelf Immunotherapy Approach,” is now freely available online and demonstrates the therapeutic potential of CytoMed’s allogeneic γδ T cell therapy (CTM‑GDT) for AML.
The research shows that CTM‑GDT can target AML cells in preclinical models, providing a strong rationale for advancing the therapy into clinical trials. Dr. Zeng Jieming, Chief Scientific and Medical Officer, noted that the findings support further clinical development of CTM‑GDT and complement the ongoing Phase 1 trial of CytoMed’s lead product, CTM‑N2D, which is currently in Singapore.
The publication marks a key milestone in CytoMed’s pipeline, expanding its focus from solid tumors to hematologic malignancies. It strengthens the company’s position as a leader in off‑the‑shelf γδ T cell therapies and may accelerate the timeline for regulatory submissions and market entry for its next product candidates.
The study underscores the potential for a scalable, donor‑derived cell therapy that could address unmet needs in AML, a disease with limited treatment options. The collaboration with MD Anderson also enhances credibility and may facilitate future clinical collaborations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.